ApoB Test Prevents More Heart Attacks Than LDL: Study
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Northwestern Medicine researchers concluded in a JAMA-published study that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current LDL or non-HDL approaches, while delivering what the authors called good value for U.S. healthcare payers.
- Lead author Ciaran Kohli-Lynch, assistant professor of preventive medicine at Northwestern's Feinberg School of Medicine, said apoB is a stronger risk indicator because it counts the total number of harmful cholesterol-carrying particles rather than just the cholesterol mass inside them.
- The study's computer simulation modeled 250,000 U.S. adults eligible for statin therapy without existing cardiovascular disease, comparing three treatment targets: LDL cholesterol under 100 mg/dL, non-HDL under 118 mg/dL, and apoB under 78.7 mg/dL.
- Patients who missed their assigned target had treatment escalated first to stronger statins, then to ezetimibe if needed, with researchers tracking lifetime heart attacks, strokes, life expectancy, quality of life, and healthcare costs across all three strategies.
- ApoB is not routinely used in U.S. care, and Kohli-Lynch flagged that the test requires an extra blood draw beyond the standard cholesterol panel — a cost and inconvenience the new analysis argues is justified.
- The American Heart Association and 10 other medical organizations released updated guidelines earlier this year recommending many people begin cholesterol-lowering therapy at younger ages, a shift the authors say makes accurate risk identification increasingly consequential.
- Co-authors Drs. John Wilkins and Samuel Luebbe contributed to the analysis, which was supported by AHA Career Development Award 24CDA1274989.
Why it matters: Heart disease remains the leading cause of death in the U.S., and the simulation of 250,000 adults shows apoB-guided treatment intensification prevents more cardiovascular events than the LDL approach now standard — at a cost the researchers deem good value for U.S. healthcare payers. The friction point is logistical: the better test requires an extra blood draw, and adoption would require payers and clinicians to change a deeply entrenched screening habit.
